Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
"Heptovax" Phase II open-label study of GV1001 in advanced hepatocellular carcinoma
2006-002211-26Phase 2Active
- Sponsor
- Pharmexa
- Start
- Jul 2006
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tertomotide in hepatocellular carcinoma (HCC), sponsored by Pharmexa. Primary endpoint: Tumor response by modified RECIST. Started Jul 2006; status: active.
02
Drugs
tertomotide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2006-002211-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002211-26.